Take a look at our previous reports:

The Galapagos share

Galapagos NV (ticker: GLPG) has been listed on Euronext Amsterdam and Brussels since 6 May 2005 and on the Nasdaq Global Select Market since 14 May 2015. Galapagos NV forms part of the Bel20 index (top 20 listed companies) on Euronext Brussels, the AMX Index (Amsterdam Midcap-index) on Euronext Amsterdam, and the NBI (Nasdaq Biotechnology Index) on Nasdaq in New York.

The Galapagos share in 2021

The Galapagos share (line chart)

In 2021, the average daily trading volume on Euronext was 436,605 shares and €26.1 million turnover. The daily trading volume on Nasdaq in 2021 was 279,359 ADSs and $19.5 million turnover.

Galapagos vs Next Biotech Index in 2021

Galapagos vs Next Biotech Index (line chart)

Galapagos vs Nasdaq Biotechnology Index in 2021

Galapagos vs Nasdaq Biotechnology Index (line chart)

Investor relations activities

In 2021 we attracted additional coverage from sell-side analysts. Currently, 17 analysts cover the Galapagos stock.

Our IR team presented at 30 (virtual) conferences in 2021 in Europe and the U.S. Several broker-organized and self-organized roadshows and virtual meetings were held throughout the U.S., Europe, and Asia, during which we held approximately 600 meetings.

We organized webcasts to present our 2020 Full Year, and our 2021 Q1, Half Year, and Q3 results, and certain conference presentations.

The main topics of discussion with investors in 2021 included the launch of Jyseleca (filgotinib) in RA in Europe and the approval of Jyseleca for the treatment of UC by the European Union, the collaboration with partner Gilead (including the extension of the lock-up period), the refocusing of our pipeline and rightsizing of our operations, the early clinical activity observed with our SIK program with SIK2/3 inhibitor GLPG3970, the positive topline results with our selective TYK2 inhibitor GLPG3667, and the planned departure of our CSO and planned retirement of our CEO and founder.

Formerly known as GLPG0634, commercial name is Jyseleca. Small molecule preferential JAK1 inhibitor, approved in RA in European Union, Great Britain, and Japan, and in UC in European Union and Great Britain. Application for approval for ulcerative colitis was filed in Japan. Filgotinib is partnered with Gilead. Filgotinib currently is in Phase 3 trials in CD, and in a Phase 4 trial in RA
A TYK2 kinase inhibitor discovered by us, topline results from the Phase 1b in psoriasis reported in July 2021
A SIK2/3 inhibitor in multiple Phase 2 Proof of Concept studies. Topline results from the studies in UC, psoriasis and RA were reported in July 2021. The compound was discontinued in March 2022
Salt-inducible kinase. This is the target family for the portfolio of molecules in the Toledo program